Glenmark Pharma receives USFDA approval for Ezetimibe

Glenmark Pharmaceuticals has received final USFDA approval for Ezetimibe and Simvastatin tablets, used for treating high levels of cholesterol in the blood. The approved product is a generic version of MSD International’s Vytorin tablets.

The product will be manufactured in the strengths of 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg.

According to market estimates, Vytorin tablets’ market achieved annual sales of approximately $92.4 million for the 12-month period ended April 2019.

Company Profile : Glenmark Pharma Ltd

Be the first to comment

Leave a Reply

Your email address will not be published.